The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 340:61-62 January 7, 1999 Number 1
NextNext

Fatal Hematoma during Treatment with Adjusted-Dose Subcutaneous Heparin Therapy

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Subcutaneous heparin therapy for atrial fibrillation, deep-vein thrombosis, unstable coronary syndromes, or ischemic cerebral attacks may be an alternative to intravenous treatment, if there are contraindications to oral anticoagulants and mobilization of the patient or discharge from the hospital is desired. Unfortunately, few studies support this practice.

With the method of adjusted-dose treatment with heparin, the drug is given subcutaneously, and the partial-thromboplastin time is monitored. Daily adjustment of the dose can result in effective prolongation of the partial-thromboplastin time. The same prophylactic effect is expected with the adjusted-dose method as with the well-studied intravenous use of . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.